8-KOther EventsExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Mar 31, 2006)

Filed March 31, 2006For Securities:BSX

Summary

Boston Scientific Corporation (BSX) filed an 8-K on March 31, 2006, to report on the outcome of special stockholder meetings held on March 30, 2006. The primary focus of the report is the approval by Boston Scientific stockholders to amend the company's Second Restated Certificate of Incorporation. This amendment will significantly increase the number of authorized shares of common stock from 1.2 billion to 2 billion. This share increase is directly linked to Boston Scientific's proposed acquisition of Guidant Corporation. The increase in authorized shares is a prerequisite for issuing new BSX common stock to Guidant shareholders as part of the merger agreement. The report also confirms that Guidant shareholders have approved the merger agreement, signifying a major step forward in the acquisition process. Investors should note that this filing primarily concerns corporate governance and procedural steps related to the Guidant acquisition, not new financial performance data.

Key Highlights

  • 1Boston Scientific stockholders approved an amendment to increase authorized common stock from 1.2 billion to 2 billion shares.
  • 2This share increase is necessary for the planned acquisition of Guidant Corporation.
  • 3Guidant Corporation stockholders also approved the merger agreement.
  • 4The filing confirms the procedural approvals for the BSX-Guidant merger are progressing.
  • 5The report is an 8-K detailing outcomes of special stockholder meetings.
  • 6No new financial results or performance metrics are presented in this filing.

Frequently Asked Questions

The main purpose of this 8-K filing is to report the outcome of special stockholder meetings for Boston Scientific Corporation and Guidant Corporation. Specifically, it announces that both sets of stockholders have approved key steps necessary for Boston Scientific's acquisition of Guidant.

Boston Scientific needed to increase its authorized shares from 1.2 billion to 2 billion to facilitate the issuance of new common stock to Guidant Corporation shareholders as part of the merger consideration. This increase ensures that enough shares are available to complete the acquisition.

No, this 8-K filing does not provide new financial results or performance metrics for Boston Scientific. Its focus is on corporate actions and approvals related to the Guidant acquisition, specifically stockholder votes and amendments to corporate documents.

Following this filing, both Boston Scientific and Guidant stockholders have approved the merger agreement. This indicates that significant procedural and corporate governance hurdles for the acquisition have been cleared, moving the deal closer to completion, although other conditions may still apply.